中文版English

Home | Add to Favorites | Contact Us

Home >> Department >> Innovation Platform >> Beijing Key Laboratory of Drug Delivery Technology and Novel Formul…

Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations

 

Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations was approved to establish in May 2011, relying on the Pharmaceutical Department, a key discipline accredited by the Ministry of Education, and the doctoral program of Pharmaceutics in the Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College.
The lab is led by the director, Professor Liu Yuling, and steered by an academic advisory committee chaired by Professor Zhang Qiang from the College of Pharmacy in Beijing University (Director of the Committee of Pharmaceutics in Chinese Pharmaceutical Association). Now, there are more than 40 scientific and technical staff and graduate students in the lab, including 4 full professors, 4 associate professors, 2 Ph.D. supervisors and 4 M.Sc. supervisors.
Mission and Target: The mission of the lab is to explore novel technology in pharmaceutics and search for novel carriers for drug delivery, to break through the limitations of physical and chemical properties or pharmacokinetical characterizations in the development of new drugs and novel preparations, and to build the new Drug Delivery System (DDS) technology platforms for new drug design and novel preparations.
Platform Construction: During the past five years, the lab has undertaken many major granted projects at national or provincial and ministerial levels, including State 863 Project, National Key Specific Programs in the 11th and 12th Five Year Plan, Beijing Specific Program of novel drugs and microparticle delivery system, and the program of “Ten Diseases and Ten Drugs”. More than 30 master and doctoral students graduated from here, and over 100 scientific papers have been published. Besides, the lab has applied for approximate 30 patents, among which 10 were granted.
Technology platforms have been successfully established, including Evaluation of Physical and Chemical Properties and Permeabilities of Preformulation, Solubilization Technology of insoluble pharmaceutical microparticles, preparation of osmotic pump-controlled release, fat emulsion as drug carrier and key technology, novel preparations of proteins and peptides, microparticles’ tumor- targeting delivery system, and genes delivery. Moreover, the lab also managed to develop many new drugs and preparations with independent intellectual property rights.
Advantage and Perspective: The research team always adheres to the development strategy, advocating the combination of the progressiveness and innovativeness, and the maturity, matching and applicability of technology with clinical and market as direction. The team is committed to go into the enterprises’ value chain.
Launched by our lab, the development of novel hypoglycemic Traditional Chinese Medicine (TCM), Mulberry Twig Total Alkaloids Tablets, has made breakthrough progress in the most leading area of Phase II clinical trials and has established a new model for modern research of TCM. The self-innovated product, novel tumor-targeted paclitaxol emulsion, has caught up with and surpassed the internationally recognized paclitaxol albumin nanoparticles with its supreme functions of alleviating allergy, increasing the tolerance dose, reducing the toxicity and side effects, and improving the anti-tumor capacity, and has thus laid a solid foundation for its international development.
The excellent outcomes of innovation have attracted many major social capitals to invest on building factories in Beijing, setting a model for the central institutes to base in the city and transform their scientific research fruits. Directed by the concept of project cooperation, the lab collaborated with a great number of enterprises on setting co-constructed labs, in order to establish a real alliance of Industry-University-Research and promote an insightful discussion about the optimal mode of the lab’s economic development.
In the coming five years, the key lab will properly integrate the resource and make great effort to produce top-star drugs, so as to play a vital role in promoting the upgrading of the pharmaceutical industrial structure in Beijing.